心力衰竭中的交感神经系统:治疗的目标
Muhammad Sameer Arshad1, Veraprapas Kittipibul2,3, Marat Fudim4,5
1Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Current hypertension reports
|July 21, 2025
概括
神经调节疗法在通过减少交感神经系统过度活跃来管理心力衰竭方面表现有前途. 需要进一步的研究来优化患者选择,并证明长期有效性以改善结果.
科学领域:
- 心脏病学 心脏病学
- 神经学 神经学
- 自主神经系统研究 自主神经系统研究
背景情况:
- 心力衰竭 (HF) 涉及自主神经系统 (ANS) 失衡,特别是慢性交感神经系统 (SNS) 过度活动.
- 这种过度活动导致心脏重塑不适应性,心律失常和血液动力学不稳定性.
研究的目的:
- 审查当前和新兴的神经调节疗法对HF.
- 讨论未来开发的新疗法,以高频率的ANS功能障碍为目标.
主要方法:
- 对高频率神经调节干预措施的现有文献的审查.
- 对新兴疗法的分析,包括基因疗法和内血管巴罗反射激活疗法 (BAT).
主要成果:
- 神经调节疗法 (SNM,VNS,BAT,RDN) 降低了同情输出,改善了高频率患者的心脏功能和血液动力学.
- 目前的实施受到响应变化,患者选择挑战和长期数据不足的限制.
- 新兴的基因疗法和内血管BAT显示出减少交感过度激活和改善HF症状和功能的潜力.
结论:
- 神经调节是管理由自主功能障碍驱动的HF的一个关键策略.
- 对HF进展和生存的长期影响需要进一步证明.
- 未来的研究必须专注于患者选择的深度表型,比较试验和大规模研究,以优化程序并评估长期疗效.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
511
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
511
Heart Failure Drugs: β-Blockers
435
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
435
Heart Failure V: Medical Management
26
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
26
Heart Failure VI: Adjunct Therapies
29
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
29
Heart Failure Drugs: Inotropic Agents
732
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
732
Heart Failure II: Pathophysiology
45
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
45


